<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862845</url>
  </required_header>
  <id_info>
    <org_study_id>NTY-2021</org_study_id>
    <nct_id>NCT04862845</nct_id>
  </id_info>
  <brief_title>Combination of Duloxetine and Pregabalin to Improve Postoperative Pain</brief_title>
  <official_title>Effect of Combination of Duloxetine and Pregabalin to Improve Pain After Liposuction Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative pain is mediated by different mechanisms at multiple neural sites. Thus,&#xD;
      multimodal analgesics can reduce the postoperative pain. Although Opioids are considered the&#xD;
      analgesics of choice to treat moderate to severe pain, their use carries the risk of side&#xD;
      effects and hyperalgesia. Multimodal analgesia can be achieved by combining different&#xD;
      analgesics and different methods of administration, to provide better analgesia&#xD;
      synergistically compared with conventional analgesia. Therefore,lower doses for each drug can&#xD;
      be provided with fewer overall side-effects obtained from individual compounds.&#xD;
&#xD;
      Recently, antidepressants such as duloxetine, a selective serotonin and norepinephrine&#xD;
      reuptake inhibitor (SSNRI), have accomplished pain relief in persistent and chronic pain as&#xD;
      in fibromyalgia, postherpetic neuralgia, diabetic neuropathy, osteoarthritis and&#xD;
      musculoskeletal pain. The analgesic effect of duloxetine is attributed to its ability to&#xD;
      enhance both serotonin and norepinephrine neurotransmission in descending inhibitory pain&#xD;
      pathways. Moreover, some studies have promoted its use to improve the quality of recovery&#xD;
      after surgery and reduce the acute postoperative pain after knee replacement surgery ,&#xD;
      mastectomy , hysterectomy , and after spine surgery. In addition it can improve postoperative&#xD;
      quality of recovery through mood improvement that can be helpful in the postoperative period.&#xD;
&#xD;
      The main objective of the present study was to examine perioperativelythe analgesic efficacy&#xD;
      with the combination of duloxetine and prgabalinon postoperative pain when given as part of a&#xD;
      multimodal pain strategy in patients undergoing surgery on liosuction. In addition to&#xD;
      evaluating the patient's satisfaction and the adverse effects related to the combination of&#xD;
      both medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total morphine consumption by( mg ) over 5 day</measure>
    <time_frame>5 days</time_frame>
    <description>Postoperative morphine consumption mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to 1st request of rescue analgesia.</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to 1st request of rescue analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>24 hous</time_frame>
    <description>visual analog scale (VAS) score of pain (0 being 'no pain' and '10' being the maximal worst pain )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total intraoperative fentanyl consumption (microgram) during surgery</measure>
    <time_frame>24 hous</time_frame>
    <description>fentanyl used</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Patients in group I (PD group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients in group II (P group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients in group III (C groups)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine and Pregabalin</intervention_name>
    <description>will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.</description>
    <arm_group_label>Patients in group I (PD group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.</description>
    <arm_group_label>patients in group II (P group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sham</intervention_name>
    <description>received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.</description>
    <arm_group_label>patients in group III (C groups)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients aged from 18 to40 years.&#xD;
&#xD;
          -  ASA I-II.&#xD;
&#xD;
          -  undergoing elective mega -liposuction surgery&#xD;
&#xD;
          -  BMI from 18 to 50 kg/m2&#xD;
&#xD;
             2. Exclusion criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Contraindication or chronic use (consistent use for longer than 3 months) to any of&#xD;
             the study drugs ASA III-IV.&#xD;
&#xD;
          -  Patients aged less than 18 or more than 40.&#xD;
&#xD;
          -  Body mass index &gt;50.&#xD;
&#xD;
          -  Suffered from severe psychiatric disease or drug addiction;&#xD;
&#xD;
          -  Chronic opioid consumption,&#xD;
&#xD;
          -  a history of regular sedatives or anticonvulsants intake, serious organ disease or&#xD;
             dysfunction&#xD;
&#xD;
          -  inability to use a PCA device&#xD;
&#xD;
          -  History of parenteral or oral analgesic intake within the last 48hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amr wahdan</last_name>
    <phone>01001422499</phone>
    <email>amr_amw010@hotmail.com</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amr Samir Wahdan</investigator_full_name>
    <investigator_title>lecture of anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

